Pfizer returns Exubera to Nektar
Executive Summary
Pfizer and Nektar resolve all outstanding contractual issues related to Exubera and Nektar's Phase I next generation inhaled insulin, which was halted after Pfizer discontinued return of Exubera in October (1"The Pink Sheet" Oct. 22, 2007, p. 4). Pfizer will make a $135 million one-time payment and agrees to return remaining rights to Nektar if the firm selects a new Exubera partner. The firms will continue with other joint projects such as a pegylated human growth hormone therapy to treat short stature and growth problems, currently in Phase II trials...
You may also be interested in...
As Pfizer Closes Door On Exubera, Has Window Opened For Others?
Pfizer's decision to terminate its Exubera program - the first inhaled insulin product to hit the market - could provide an opportunity for other drug makers looking to step into the market, especially those prepared to address obstacles illuminated by Pfizer
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.